DR-0201 in Subjects With Autoimmune Diseases

PHASE1RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

March 27, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
SLESLE (Systemic Lupus)CLECutaneous LupusSjogren's SyndromePrimary Sjögren SyndromeDermatomyositisPolymyositisSclerodermaSSc, Diffuse SclerosisdcSScDiffuse Cutaneous Systemic Sclerosis
Interventions
DRUG

DR-0201

DR-0201 is a bispecific antibody

Trial Locations (8)

1935

NOT_YET_RECRUITING

Dren Investigational Site, Vereeniging

3004

RECRUITING

Dren Investigational Site, Melbourne

4151

RECRUITING

Dren Investigational Site, Coorparoo

71000

RECRUITING

Dren Investigational Site, Sarajevo

88000

RECRUITING

Dren Investigational Site, Mostar

0622

RECRUITING

Dren Investigational Site, Auckland

0699

NOT_YET_RECRUITING

Dren Investigational Site, Polokwane

0002

RECRUITING

Dren Investigational Site, Pretoria

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Dren Bio

INDUSTRY

NCT06647069 - DR-0201 in Subjects With Autoimmune Diseases | Biotech Hunter | Biotech Hunter